ABCELLERA BIOLOGICS INC

Abcellera Biologics Inc. specializes in advanced research and development in biotechnology, with a focused expertise in the discovery and characterization of human antibodies using transgenic mouse platforms. Their technical capabilities center on generating fully human monoclonal antibodies through genetically engineered mouse models, enabling the rapid identification of high-affinity therapeutic candidates targeting human genome-derived antigens. This work supports the development of precision biologics for infectious diseases, oncology, and autoimmune disorders, leveraging cutting-edge immunological screening and high-throughput antibody isolation technologies. Their differentiation lies in the integration of transgenic systems with functional screening platforms to accelerate the transition from target identification to lead candidate selection. The company has delivered research services to the Department of Health and Human Services, primarily supporting antibody discovery initiatives aligned with public health priorities. The awarded project involving transgenic mice for human genome antibodies indicates a direct alignment with HHS’s mission to advance biomedical innovation for therapeutic development, suggesting a relationship grounded in mission-critical, non-clinical R&D support. Abcellera operates primarily under NAICS 541714, which encompasses biotechnology research focused on antibody engineering and humanized model systems—distinct from nanobiotechnology. This positions them as a niche provider in the preclinical antibody discovery space, serving government and pharmaceutical partners requiring scalable, human-relevant biological platforms. As a privately held entity based in Vancouver, BC, Abcellera Biologics Inc. maintains no federal small business certifications. Their geographic presence is centered in Canada, with their government market engagement limited to U.S. federal agencies through contractually scoped research collaborations. Their operational model reflects a specialized R&D service provider with deep technical capability in antibody discovery platforms, serving strategic public health objectives without broad commercial or certification-based market expansion.